Cardiol Therapeutics (TSE:CRDL) Stock Price Up 1.6%

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) rose 1.6% during mid-day trading on Tuesday . The company traded as high as C$3.10 and last traded at C$3.09. Approximately 75,371 shares changed hands during trading, a decline of 50% from the average daily volume of 150,386 shares. The stock had previously closed at C$3.04.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating on shares of Cardiol Therapeutics in a research report on Monday, April 22nd.

Cardiol Therapeutics Price Performance

The company’s 50-day moving average price is C$3.05 and its 200-day moving average price is C$2.46. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.81 and a quick ratio of 6.84. The company has a market cap of C$213.90 million, a P/E ratio of -6.60 and a beta of 0.68.

Insider Transactions at Cardiol Therapeutics

In related news, Director David Elsley acquired 50,000 shares of the stock in a transaction dated Monday, June 24th. The stock was bought at an average price of C$2.77 per share, with a total value of C$138,490.00. 4.42% of the stock is owned by insiders.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.